"This analysis explores the critical shifts in the sector, highlighting a projected growth trajectory driven by technological integration and changing consumer dynamics."

According to analysts at Vantage Market Research, the United States Cell and Gene Therapy Market size was estimated at USD 12.8 billion in 2025 and is projected to reach USD 54.6 billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 15.6% from 2026 to 2035. Key trends include expanding commercial approvals, manufacturing modernization, precision medicine initiatives, AI-enabled manufacturing analytics, scalable production platforms, vertically integrated development ecosystems, advanced vector technologies, digital quality management, supply-chain resilience, and increasing adoption of specialized treatment infrastructure.

United States Cell and Gene Therapy Market Overview

The United States Cell and Gene Therapy Market has evolved into one of the most strategically important segments within advanced biopharmaceutical innovation. Growing enterprise investment in therapies capable of addressing complex diseases with limited treatment alternatives is strengthening demand across therapeutic development, manufacturing, clinical delivery, logistics, and supporting technology ecosystems.

Commercial activity is increasingly extending beyond therapeutic discovery toward manufacturing scalability, vector development, automated production, analytical characterization, specialized logistics, and integrated digital quality management. Pharmaceutical companies, biotechnology developers, healthcare providers, contract development and manufacturing organizations, and academic institutions are increasingly aligning their investments with platforms capable of accelerating commercialization while maintaining consistent product quality.

Manufacturing modernization is emerging as a major growth catalyst. The transition toward modular cleanroom infrastructure, automated cell-processing systems, closed-system manufacturing, digital manufacturing execution platforms, real-time quality monitoring, and advanced analytics is improving batch consistency and reducing operational variability. Organizations are increasingly prioritizing scalable manufacturing capabilities and supply-chain resilience when selecting technology and production partners.

Expanding commercial approvals and precision medicine initiatives are also supporting market expansion. Cell-based therapies continue to demonstrate strong commercial adoption across oncology and regenerative medicine applications, while gene therapy pipelines are expanding across rare genetic disorders, neurological diseases, ophthalmology, and inherited metabolic conditions.

Artificial intelligence and digital technologies are further transforming operational workflows. AI-enabled production scheduling, predictive maintenance, digital quality assurance, process optimization, and manufacturing analytics are improving resource utilization and supporting regulatory documentation. These capabilities are strengthening manufacturing efficiency while enabling organizations to manage increasingly complex therapeutic portfolios.

The United States remains a leading global market due to its advanced biopharmaceutical ecosystem, substantial R&D investment, strong regulatory infrastructure, specialized treatment centers, and expanding commercial manufacturing capacity. Overall, the market is expected to experience robust long-term growth as pharmaceutical companies and healthcare organizations continue investing in scalable production, precision medicine, advanced therapeutic platforms, and integrated commercialization ecosystems.

Gilead Sciences Advances Digital Manufacturing Systems to Strengthen Cell and Gene Therapy Production Efficiency

January 2026 — Gilead Sciences enhanced digital manufacturing systems to optimize quality management, improve batch consistency, and strengthen operational efficiency across advanced therapeutic production.

Key Takeaways from the Report

Cell Therapy represented nearly 61% of industry revenue, reflecting broad commercialization across oncology and regenerative medicine applications.
Gene Therapy is projected to record the fastest expansion at approximately 17.8% CAGR through the forecast period due to expanding genetic medicine pipelines.
AI-enabled manufacturing analytics influenced more than 55% of newly deployed production optimization initiatives, strengthening operational efficiency.
Over 72% of commercial procurement programs emphasized scalable manufacturing capability and supply-chain resilience during vendor selection.
More than 68% of enterprise investment strategies prioritized vertically integrated development ecosystems, reinforcing commercialization readiness.
Manufacturing modernization is accelerating through automated cell processing, modular cleanrooms, closed-system technologies, digital quality management, and real-time production monitoring.
Expanding reimbursement pathways and institutional healthcare investment are supporting greater adoption of advanced therapies with durable clinical outcomes.
Supply-chain resilience, cryogenic logistics, chain-of-identity management, and specialized storage capabilities are becoming increasingly important procurement priorities.
AI, advanced analytics, and digitally connected manufacturing platforms are creating new opportunities for improving production efficiency, regulatory readiness, and commercialization scalability.
Strategic collaborations among biotechnology companies, biopharmaceutical manufacturers, CDMOs, healthcare providers, and academic institutions are strengthening the broader therapeutic ecosystem.

Top Players

Bristol Myers Squibb
Gilead Sciences
Novartis AG
Pfizer Inc.
Johnson & Johnson
Bluebird Bio
Sarepta Therapeutics
CRISPR Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Beam Therapeutics
Legend Biotech
Catalent
Lonza Group
WuXi Advanced Therapies

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events such as the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest Announcements

May 2026 — Catalent increased advanced therapy manufacturing capacity through facility upgrades supporting commercial-scale production and expanding its capabilities for cell and gene therapy developers.